Product Images Losartan Potassium
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 7 images provide visual information about the product associated with Losartan Potassium NDC 66336-665 by Dispensing Solutions, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
NDC 66336-0665-XX - NDC 66336 0665 XX TEVA
This is a bulk source data for medications manufactured for Teva Pharmaceuticals in Sellersville, PA. One of the products is a green oval-shaped film-coated tablet with a 93/7365 imprint and NDC number 00093-7365-10. The medication should be dispensed in a tight and light-resistant container and taken orally according to a physician's advice, warning of possible dizziness, and drowsiness. Another product is Losartan Potassium 50mg in tablet form with NDC 66336-0665-XX and a unique product number of 685-XX. It contains FD&C Yellow No. 6 and is only for use under medical supervision. It should be kept out of reach of children and stored at temperatures between 68°-77° F, with an expiry date of 00-00. There are multiple lots with different RX# numbers.*
NDC 66336-0666-XX - NDC 66336 0666 XX TEVA
This is a bulk source data sheet for Losartan Potassium 25mg tablets manufactured for Teva Pharmaceuticals USA. The tablets are green, oval-shaped, and film-coated with markings 93/7364. The tablets are dispensed in a tight and light resistant container, and each contains Losartan Potassium USP at 25 mg strength. The sheet includes product information such as lot numbers, expiration dates, and Rx numbers, and also includes a warning to keep medications out of children's reach and to store them within a specific temperature range.*
Chem Structure for losartan potassium - b1af6b4b 2a05 41d3 bc65 f6b83f6daa92 01
FIgure 1 - b1af6b4b 2a05 41d3 bc65 f6b83f6daa92 02
This text seems to be a result of a study where two medications - Atenolol and Losartan potassium - were tested on patients with a primary endpoint. The study was conducted for 66 months and the adjusted risk reduction was 13% with a p-value of 0.021. It is not clear what the primary endpoint refers to or what condition is being treated.*
Figure 2 - b1af6b4b 2a05 41d3 bc65 f6b83f6daa92 03
This is a study that compares the effectiveness of Atenolol and Losartan Potassium in reducing the risk of fatal and non-fatal stroke. The data shows an adjusted risk reduction of 25% with a p-value of 0.001. The study was conducted for 66 months, with data collected at various intervals from month 6 to month 66.*
Figure 3 - b1af6b4b 2a05 41d3 bc65 f6b83f6daa92 04
Figure 4 - b1af6b4b 2a05 41d3 bc65 f6b83f6daa92 05
This text appears to be a chart or graph comparing the risk reduction percentage of patients who had an event while taking Losartan Potassium versus a placebo over a period of 24 months. The chart also includes some data points at 36 and 48 months. The overall reduction was 16.1% with a significance level of p=0.022.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.